#USA #Fremont #Alamar Biosciences #Biomarkers #NULISAqpcr

Alamar Biosciences Unveils the NULISAqpcr™ Custom Assay Development Kit

Alamar Biosciences, a pioneering player in the realm of precision proteomics, has recently introduced its latest offering, the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking kit empowers researchers to craft highly sensitive and specific biomarker tests tailored to their unique research requirements, systematically expanding the capabilities of the NULISA™ technology across the global biomarker research community.

The NULISA™ platform is distinguished by its ability to achieve attomolar sensitivity, setting a new benchmark in proteomic analysis. This level of sensitivity facilitates previously unattainable detection and quantification of biomarkers. The versatility of the NULISAqpcr™ kit offers scientists unparalleled flexibility, allowing them to employ their own antibodies to develop custom assays that provide exceptional sensitivity and reproducibility.

As scientific research evolves, the demand for customizable solutions in areas such as immunology, neurology, and various other fields has been on the rise. The NULISAqpcr™ kit meets this demand effectively, offering a seamless operational workflow from antibody conjugation to automated NULISAqpcr using the ARGO™ HT instrument. This innovation is poised to set a new standard for the development of customized singleplex tests.

Dr. Yuling Luo, founder and CEO of Alamar Biosciences, stated, "The release of the Custom Assay Development Kit directly addresses the increasing requests from researchers eager to utilize our cutting-edge NULISA technology for high-performance biomarker testing in both translational and clinical research. This launch signifies a significant milestone in our mission to build a transformative ecosystem for precision proteomics."

The NULISAqpcr™ kit is now available for order, with deliveries slated for the second quarter of 2025. This release reiterates Alamar’s commitment to fostering innovation and support for the scientific community through state-of-the-art solutions.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company with a mission to develop precision proteomics to enable the early detection of diseases. The proprietary NULISA™ platform, coupled with the ARGO™ HT system, integrates seamlessly with the latest advancements in genomics to achieve one-digit attomolar detection sensitivity, surpassing the market's most sensitive protein detection technologies. For more detailed information, you can visit alamarbio.com. To witness the innovation, check out the product video here.